Trial record 1 of 1 for:    NCT03480646
Previous Study | Return to List | Next Study

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03480646
Recruitment Status : Recruiting
First Posted : March 29, 2018
Last Update Posted : August 3, 2018
Information provided by (Responsible Party):
Constellation Pharmaceuticals

Brief Summary:

This is a two-arm, open label phase 1b/2 with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone.

Following determination of MTD and RP2D will proceed to phase 2. Patients in phase 2 will receive CPI-1205 at the RP2D in combination with either enzalutamide or abiraterone/prednisone.

Condition or disease Intervention/treatment Phase
Metastatic Castration Resistant Prostate Cancer (mCRPC) Drug: CPI-1205 Drug: Enzalutamide Drug: Abiraterone/Prednisone Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Actual Study Start Date : November 15, 2017
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CPI-1205 Combination with Enzalutamide Drug: CPI-1205
Administered orally

Drug: Enzalutamide
Administered orally

Experimental: CPI-1205 Combination with Abiraterone/Prednisone Drug: CPI-1205
Administered orally

Drug: Abiraterone/Prednisone
Administered orally

Primary Outcome Measures :
  1. Frequency of Dose-limiting toxicities (DLTs) [ Time Frame: 1 year ]
    The RP2D will be selected based on the overall tolerability of each of the combinations (i.e with either enzalutamide or abiraterone/prednisone), but will not exceed the MTD will be selected based on PK and the overall tolerability of the combination, but will not exceed the MTD.

Secondary Outcome Measures :
  1. PSA50 [ Time Frame: 1 year ]
    The proportion of patients with a ≥50% reduction in PSA from baseline.

  2. Time to PSA progression [ Time Frame: 1 year ]
  3. Radiographic progression free survival [ Time Frame: 1 year ]
  4. Objective response rate [ Time Frame: 1 year ]
    The proportion of patients with a CR or PR per PCWG3.

  5. Time to first skeletal-related event (SRE) [ Time Frame: 1 year ]
  6. Time to first symptomatic skeletal event (SSE) [ Time Frame: 1 year ]
  7. Time to clinical progression [ Time Frame: 1 year ]
  8. Time to initiation of new systemic treatment for prostate cancer [ Time Frame: 1 year ]
  9. To further evaluate the Incidence of Treatment-Emergent Adverse Events (safety and tolerability) [ Time Frame: 1 year ]
    Adverse Events

  10. Pharmacokinetic parameters [ Time Frame: 1 year ]
    Area under the concentration versus time curves (AUC)

  11. CTC [ Time Frame: 1 year ]
    In patients who enter the trial with unfavorable CTCs (five or more cells per 7.5mL of blood), conversion to favorable status is defined as four or fewer cells per 7.5 mL of blood. The CTC conversion rate is the proportion of patients who convert to favorable status.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults (Age ≥ 18 years)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Histologically or cytologically confirmed adenocarcinoma of the prostate
  • Progressive disease in the setting of medical or surgical castration (i.e., CRPC)
  • Documented metastatic disease (may be measurable or non-measurable)
  • Must have undergone bilateral orchiectomy (surgical castration) or be willing to continue gonadotropin-releasing hormone (GnRH) analog or antagonist (medical castration)
  • Serum testosterone <50 ng/dL
  • Demonstrate adequate organ function as defined below:
  • Absolute Neutrophil Count (ANC) ≥ 1,000/μL
  • Platelet Count ≥ 100,000/μL
  • Hemoglobin (Hgb) ≥ 8 g/dL
  • Serum creatinine ≤ 2 × upper limit of normal (ULN) OR
  • Creatinine clearance (CrCl) ≥ 40 mL/min as estimated by the Cockcroft and Gault formula1 in subjects with creatinine > 2 X ULN
  • Bilirubin ≤ 1.5 × ULN unless evidence of Gilbert's disease in which case < 3 x ULN
  • Aspartate aminotransferase (AST) ≤ 2.5 × ULN without liver metastases; must be ≤ 5 × ULN with liver metastases
  • Alanine aminotransferase (ALT) ≤ 2.5 × ULN without liver metastases; must be ≤ 5 × ULN with liver metastases

Exclusion Criteria:

  • Known symptomatic brain metastases (NOTE: patients with treated epidural disease are allowed)
  • Receipt of >1 line of therapy that includes a second generation androgen inhibitor for treatment of mCRPC
  • Treatment with any of the following for prostate cancer within 4 weeks prior to day 1 of treatment:

    1. First generation: AR antagonists (e.g., bicalutamide, nilutamide, flutamide), 5 alpha reductase inhibitors, ketoconazole, estrogens (including diethylstilbesterol [DES]), or progesterones
    2. Chemotherapy
    3. Biologic therapy
    4. Saw palmetto or other therapies thought to have endocrine effects on prostate cancer
    5. Investigational therapy (NOTE: or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer).
    6. Immunotherapy
    7. Prior radiation therapy or radionuclide therapy for the treatment of metastasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03480646

Contact: Debbie Johnson 617-714-0555
Contact: David Nash

United States, Alaska
Alaska Urological Institute Recruiting
Anchorage, Alaska, United States, 99503
Contact: Talia Wyckoff    907-276-1455   
United States, Colorado
Rocky Mountain Cancer Centers Recruiting
Aurora, Colorado, United States, 80045
Contact: Patrick Ssebikejje    303-418-7643   
United States, Indiana
Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Sheri Lipps    765-298-2040   
United States, Louisiana
Tulane University Health Sciences Center Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Gaynelle Davis    504-988-6770   
United States, Maryland
University of Maryland Recruiting
Baltimore, Maryland, United States, 21201
Contact: Michele Besche   
John Hopkins Kimmel Cancer Center Recruiting
Baltimore, Maryland, United States, 21205
Contact: Rehab AbdAllah    410-955-4042   
Maryland Oncology Hematology Recruiting
Rockville, Maryland, United States, 20850
Contact: Cathleen Ganley    240-826-2140   
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Meredith Sleeper    617-632-5701   
United States, Nebraska
GU Research Network Recruiting
Omaha, Nebraska, United States, 68130
Contact: Erin Powers         
United States, New Mexico
New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: Ian Rabinowitz    505-272-4946   
United States, New York
Icahn School of Medicine at Mt. Sinai Recruiting
New York, New York, United States, 10029
Contact: Seth Cohen    212-824-8583   
United States, Oregon
Williamette Valley Cancer Institute and Research Center Recruiting
Eugene, Oregon, United States, 97401
Contact: Jeff Sharman    541-683-5001   
United States, Pennsylvania
Gettysburg Cancer Center Recruiting
Gettysburg, Pennsylvania, United States, 17331
Contact: Vanessa Warner         
United States, South Carolina
Greenville Hospital System, Institute for Translational Oncology Research Recruiting
Greenville, South Carolina, United States, 29605
Contact: Jan Kueber    864-455-3600   
Carolina Urologic Research Center Recruiting
Myrtle Beach, South Carolina, United States, 29572
Contact: Jennifer Baiden         
United States, Texas
Texas Oncology- Fort Worth Recruiting
Fort Worth, Texas, United States, 76104
Contact: Nori Sullivan    817-850-2145   
Texas Oncology- Tyler Recruiting
Tyler, Texas, United States, 75702
Contact: Shelly Maxfield    903-579-9840   
United States, Virginia
Virginia Oncology Associates Recruiting
Hampton, Virginia, United States, 23666
Contact: Karen McClain    757-827-9400   
Sponsors and Collaborators
Constellation Pharmaceuticals
Study Director: Debbie Johnson Constellation Pharmaceuticals

Responsible Party: Constellation Pharmaceuticals Identifier: NCT03480646     History of Changes
Other Study ID Numbers: 1205-201
First Posted: March 29, 2018    Key Record Dates
Last Update Posted: August 3, 2018
Last Verified: March 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Constellation Pharmaceuticals:
Phase 1/2
EZH2 Inhibitor

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents